Is Becton, Dickinson and Company Shares Beating the Dow's Performance?

Becton, Dickinson and Company: A Leading Force in Medical Technology

Headquartered in Franklin Lakes, New Jersey, Becton, Dickinson and Company (BDX) stands as a prominent global player in the medical technology sector, boasting a market capitalization of $50.3 billion. The company specializes in the development, production, and distribution of a wide array of medical devices, supplies, and interventional products.

With a valuation well above $10 billion, BDX is firmly categorized as a large-cap stock, reflecting its significant presence and leadership within the medical instruments and supplies industry. The company is committed to advancing healthcare through innovation, focusing on areas such as biologic drug delivery, automated medication management, and sophisticated patient monitoring systems. These efforts are aimed at enhancing both clinical outcomes and operational efficiency for healthcare professionals and patients alike.

Currently, BDX shares are trading 5.8% below their 52-week peak of $187.35, which was set on February 24. Over the last three months, the stock has surged by 15.8%, significantly outpacing the Dow Jones Industrial Average’s ($DOWI) 3.3% gain during the same period.

Year-to-date, BDX’s stock price has climbed 15.7%, compared to a 1.9% increase for the Dow. However, looking at the past year, BDX’s growth has been modest and trails the Dow’s 13.3% advance.

Since late November, BDX has consistently traded above its 200-day moving average, with only minor fluctuations, and has also remained above its 50-day moving average since mid-November—further supporting its positive momentum.

On February 9, despite delivering stronger-than-expected fourth-quarter results, BDX’s share price dropped by 1.3%. The company reported a 1.6% year-over-year revenue increase to $5.3 billion, surpassing analyst forecasts. Nonetheless, management expressed caution regarding ongoing global economic and regulatory challenges, particularly those related to China and vaccine demand, which may have unsettled investors. Adjusted earnings per share reached $2.91, comfortably beating the consensus estimate of $2.82.

BDX has notably outperformed its competitor, Intuitive Surgical, Inc. (ISRG), which saw its stock decline by 10.7% over the past year and by 11.1% year-to-date.

Given BDX’s recent strong performance, analysts maintain a cautiously optimistic outlook. Of the 14 analysts covering the stock, the consensus rating is “Moderate Buy,” and the average price target of $194.08 implies a potential 10% upside from current levels.